NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

Review our 9 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Posters

Preview our poster topics now covering a wide variety of preclinical oncology and immuno-oncology platforms including tumor organoids for drug discovery and I/O drug development, orthotopic syngeneic models, and immunoprofiling data.

ON DEMAND WEBINAR: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy
Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.



CrownBio の前臨床「トランスレーショナルプラットフォーム」は、候補化合物の臨床試験への移行の重要な決定を支援するための、自然発生及び食餌誘導性肥満(DIO)モデルを提供いたします。








抗糖尿病薬のin vivo有効性評価のための、従来型、及びCrownBio独自の臨床予測性が高いI 型及びII 型糖尿病のモデルを提供しています。